Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 180, Issue 2, Pages 189-200Publisher
WILEY
DOI: 10.1111/bjh.15021
Keywords
sickle cell disease; hydroxycarbamide; fetal haemoglobin; gene therapy; globin genes
Categories
Funding
- National Heart, Lung and Blood Institute [1K08DK110448-01]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK110448] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Fetal haemoglobin (HbF, alpha 2 gamma 2) induction has long been an area of investigation, as it is known to ameliorate the clinical complications of sickle cell disease (SCD). Progress in identifying novel HbF-inducing strategies has been stymied by limited understanding of gamma (gamma)-globin regulation. Genome-wide association studies (GWAS) have identified variants in BCL11A and HBS1L-MYB that are associated with HbF levels. Functional studies have established the roles of BCL11A, MYB, and KLF1 in gamma-globin regulation, but this information has not yielded new pharmacological agents. Several drugs are under investigation in clinical trials as HbF-inducing agents, but hydroxycarbamide remains the only widely used pharmacologic therapy for SCD. Autologous transplant of edited haematopoietic stem cells holds promise as a cure for SCD, either through HbF induction or correction of the causative mutation, but several technical and safety hurdles must be overcome before this therapy can be offered widely, and pharmacological therapies are still needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available